Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.

Dawson, N; Figg, W D; Brawley, O W; Bergan, R; Cooper, M R; Senderowicz, A; Headlee, D; Steinberg, S M; Sutherland, M; Patronas, N; Sausville, E; Linehan, W M; Reed, E; Sartor, O

Dawson, N; Figg, W D; Brawley, O W; Bergan, R; Cooper, M R; Senderowicz, A; Headlee, D; Steinberg, S M; Sutherland, M; Patronas, N; Sausville, E; Linehan, W M; Reed, E; Sartor, O.

Affiliation

Dawson N; Clinical Pharmacology Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA.

Clin Cancer Res ; 4(1): 37-44, 1998 Jan.

Article in En | MEDLINE | ID: mdl-9516950

Subject(s)

Aminoglutethimide/administration & dosage; Androgen Antagonists/administration & dosage; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Prostatic Neoplasms/drug therapy; Suramin/administration & dosage; Adult; Aged; Aged, 80 and over; Aminoglutethimide/adverse effects; Humans; Male; Middle Aged; Prostatic Neoplasms/mortality; Suramin/adverse effects; Survival Rate

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Suramin / Antineoplastic Combined Chemotherapy Protocols / Aminoglutethimide / Androgen Antagonists Type of study: Clinical_trials / Guideline / Risk_factors_studies Limits: Adult / Aged / Aged80 / Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 1998 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links